TSS
KTTA icon

Two Sigma Securities’s Pasithea Therapeutics KTTA Stock Holding History

Two Sigma Securities’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,846
Closed -$15.3K – 1777
2025
Q3 		$15.3K Buy
+20,846
New +$15.2K ﹤0.01% 1168
2022
Q2 		– Sell
-945
Closed -$25K – 2568
2022
Q1 		$25K Buy
+945
New +$23.9K ﹤0.01% 1949
2021
Q4 		– Sell
-522
Closed -$32K – 1812
2021
Q3 		$32K Buy
+522
New +$31.6K ﹤0.01% 1426

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

Two Sigma Securities's KTTA Position: Q4 2025 in Review

Two Sigma Securities sold out of Pasithea Therapeutics (KTTA) in Q4 2025, closing a stake of 20,846 shares — an estimated $15.3K sold.

Two Sigma Securities first reported a position in KTTA in Q3 2021 and held it in 3 quarters. The position peaked at $32K in Q3 2021. 26 funds tracked by Wall St. Rank hold KTTA as of Q4 2025.

  • Two Sigma Securities reported no remaining Pasithea Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Securities sold 20,846 Pasithea Therapeutics shares in Q4 2025, an estimated $15.3K.
  • Two Sigma Securities first reported a position in Pasithea Therapeutics in Q3 2021 and held it in 3 quarters.
  • Two Sigma Securities's Pasithea Therapeutics position peaked at $32K in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.